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Serum a2-macroglobulin and a1-inhibitor 3 concentrations are in-
creased in hypoalbuminemia by post-transcriptional mechanisms. In both
the nephrotic syndrome (NS) and hereditary analbuminemia in the
Nagase analbuminemic rat (NAR), the plasma protein concentration is
nearly normal since albumin is replaced by several high molecular weight
proteins. In rats these include the protease inhibitors a2-macroglobulin
(a2M), a 720 kDa positive acute phase protein (APP) and a1-inhibitor 3
(a1-I3), a 180 kDa negative APP. There is no known stimulus to increase
a1-I3 synthesis, but like albumin and other negative APPs its synthesis
decreases during inflammation by transcriptional down-regulation. In
hypoalbuminemic states gene transcription of other positive and negative
APPs is increased. We report that a2M was increased significantly
(12-fold) in NAR and by approximately 50-fold in rats with NS compared
to control. The a1-I3 concentration was twice normal in NAR or NS
compared to controls, providing approximately half of the total plasma
protein. Infusion of human albumin into NAR to raise albumin levels . 20
mg/ml for 24 hours caused a significant decrease in a1-I3 (24.8 6 0.6 to
18.7 6 0.6 mg/ml, P , 0.0001), equal in magnitude to that caused by 250
mg/100 g of endotoxin (23.0 6 1.1 to 18.6 6 0.6, P , 0.01). The effect of
albumin was not an acute phase response since it also suppressed a2M
(239 6 10 to 205 6 11 mg/ml, P , 0.005). Turnover of 125I labeled a2M
and a1-I3 was then measured in controls, NAR and in two models of the
nephrotic syndrome in rats (Heymann nephritis, HN; adriamycin-induced,
ADR), yielding fractional catabolic rates (FCR), which at steady state
equals synthesis. The serum a2M concentration was increased '50-fold
and was proportional to synthesis (r 5 0.91 P , 0.001). a2-Macroglobulin
synthesis increased by 12-fold in NAR and 50-fold in NS. In contrast,
hepatic a2M mRNA increased only 30% in NAR and twofold in NS,
suggesting post-transcriptional regulation. Fractional catabolic rates were
not decreased and played no role in increasing serum a2M in NS or NAR.
The a1-I3 concentration and synthesis increased twofold from controls in
both NAR and NS. However, hepatic a1-I3 mRNA was not increased in
NAR and increased only 50% in NS. Unlike a2M, serum a1-I3 correlated
negatively with FCR (2r 5 0.66, P , 0.01). In conclusion, both a1-I3 and
a2M concentration are increased in hypooncotic states by increased
synthesis regulated post-transcriptionally, supporting plasma protein con-
centration when albumin is lost in urine or not synthesized.
The nephrotic syndrome is a consequence both of altered
glomerular permselectivity, allowing plasma proteins of interme-
diate size to escape into the urine [1–3], and the alteration in
synthesis and catabolism of plasma proteins [4–6], resulting in an
increased plasma concentration of many proteins of high molec-
ular weight that are too large to be lost in the urine to any
significant extent [7]. We and others observed that total plasma
protein concentration remained well-preserved in the nephrotic
syndrome despite significant urinary loss not only of albumin, but
of transferrin [8, 9], ceruloplasmin [10–12] and immunoglobulins
[13]. Furthermore, plasma protein concentration, and even the
relationship between plasma protein concentration and colloid
osmotic pressure–oncotic pressure (p) is preserved in rats with
hereditary analbuminemia, the Nagase analbuminemic rats
(NAR) [14], suggesting that increased levels of other plasma
proteins may play a homeostatic role in preserving plasma protein
concentration or p.
We previously reported that synthesis of a group of proteins
secreted specifically by the liver, including both positive (fibrino-
gen) and negative (albumin, transferrin, and apo A-I) acute phase
proteins, was increased both in the nephrotic syndrome and in
NAR [9, 15–17]. In these cases increased synthesis was regulated
at the level of transcription [5, 9, 16–19]. This unusual pattern of
gene expression led us to hypothesize that genes encoding a
specific group of negative and positive acute phase proteins were
positively regulated in hypooncotic states, a pattern distinct from
that which occurs in the presence of inflammation.
Macroglobulins are a genetically related class of protease and
cytokine inhibitors [20, 21] that are produced primarily in the liver
[22–24]. Their synthesis is regulated either as positive (a1- and
a2-macroglobulin) [22, 25–27] or negative (a1-inhibitor 3) [28, 29]
acute phase proteins. They act as modulators of the acute phase
response [30] and bind to and moderate the function of cytokines
[30–32], a variety of growth factors [33] and potent proteases [34,
35]. It has been observed that one of these proteins, a2-macro-
globulin (a2M) is also increased in the nephrotic syndrome in
patients [36].
In the rat the predominant macroglobulin is a1-inhibitor 3
(a1-I3), a monomeric (180 kDa) negative acute phase protein
similar in structure to each of the four a2M subunits. a2-
Macroglobulin is a 720 kDa tetrameric vigorously responding
positive acute phase protein in the rat [26]. In humans with the
nephrotic syndrome, total plasma protein concentration is also
maintained by increased levels of high molecular weight globulins,
mainly a2M [36, 37]. As in humans, the level of a2M is elevated in
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nephrotic rats [38]. There is no known stimulus for synthesis of the
negative acute phase protein a1-I3 [28, 29]. The metabolism of
this protein in hypooncotic states is unknown. Our hypothesis, if it
can be extended to these protease inhibitors, would suggest that
synthesis of both a2M and a1-I3 should be stimulated at the
transcriptional level in both the nephrotic syndrome and NAR.
In these experiments, we sought to establish the basal levels of
these macroglobulins in rats with either nephrotic syndrome
[Heymann nephritis (HN) or adriamycin-induced nephrotic syn-
drome (ADR)] or NAR, and to investigate the mechanism of
changes in the serum levels of these proteins.
METHODS
Reagents
a2-Macroglobulin and a1-I3 were purified from the plasma
(ethylene diamine tetraacetic acid; Fisher Chemical Co., Fair
Lawn, NJ, USA) of 12 rats which had been injected subcutane-
ously with 0.5 c.c. of turpentine 48 to 72 hours prior to bleeding.
The chilled plasma was adjusted to 5% PEG (carbowax-PEG
8000; Fisher) by the addition of 50% PEG solution and stirred on
ice for 30 minutes. All steps were performed at 4°C. The solution
was centrifuged at 2500 rpm for 15 minutes; the supernatant was
saved and adjusted to 13% PEG, and stirred and centrifuged as
before. The pellet was dissolved in 50 mM Tris (Trizma Base;
Sigma Chemical Co., St. Louis, MO, USA), pH 7.5, 50 mM NaCl
to 1/2 the original plasma volume.
The protein solution was applied to an affi-gel Blue column (2.5
cm 3 13 cm; Bio Rad, Richmond, CA, USA) equilibrated in the
same buffer, the flow through was collected and adjusted to pH
8.0 with 1 N NaOH and applied to a DE-52 (Whatman Chemical
Co., Maidstone, UK) column (2.5 cm 3 20 cm) equilibrated in 50
mM Tris pH 8.0, 50 mM NaCl (Fischer), 0.02% NaN3 (Fischer).
After washing, elution of the two proteins was accomplished with
a gradient in 50 mM Tris, pH 8.0, from 50 mM NaCl to 250 mM
NaCl (total volume 5 500 ml). Those fractions that eluted at the
front of the rather broad peak contained a2M, while later
fractions contained a mixture of a1M and a1-I3. Sodium dodecyl
sulfate—polyacrylamide gel electrophoresis (SDS-PAGE) [39],
on both unreduced and reduced samples, was used to assess which
fractions to pool for the two proteins. Two separate pools were
made, concentrated using a Filtron centrifugal concentrator
(MWCO 5 50 kDa), and chromatographed separately on
Sephacryl S300 (2.5 cm 3 80 cm; Pharmacia Fine Chemicals,
Uppsala, Sweden). Purity was assessed by SDS-PAGE.
Polyclonal antibodies were obtained for each purified protein
by subcutaneous injection into New Zealand White rabbits by first
using complete Freund’s adjuvant followed by incomplete adju-
vant. Specificity for each antibody was established first by deter-
mining that only a single band of immunoprecipitation occurred
using the Ochterlony double diffusion technique and then by
Western blot [39]. Electroimunodiffusion assays were then devel-
oped for each protein that were both linear in the concentration
range of interest and that exhibited parallelism with diluted
controls. Care was taken not to repeatedly freeze thaw standards.
Experimental models
With the exception of NAR all rats were male Sprague Dawley
rats purchased from Bantin Kingman Farms (Fremont, CA,
USA). All studies were performed in males.
Passive Heymann nephritis. Sprague-Dawley rats weighing 120
to 150 g were injected intraperitoneally with sheep FX1A anti-
serum (Dr. Florence Hutchison, Charleston, SC, USA). Protein-
uria begins at nine days and reaches a plateau at 11 days in this
model [4]. All studies were performed after 11 days.
Adriamycin-induced nephrotic syndrome was established by
injecting 5 mg/kg of adriamycin into a tail vein approximately 21
days prior to the study [40].
Nagase analbuminemic rats (NAR) were raised in our own
colony, originally derived from a colony of animals donated to us
by Dr. Jaap Joles (Utrecht, the Netherlands). They were derived
by Cesarean section and care was taken to assure that they remain
pathogen free. Every four generations NAR males are bred with
normal Sprague-Dawley female rats and the subsequent f1 gen-
eration is back bred with NAR males. The resulting f2 generation
is subsequently tested for the presence of plasma albumin using
immunochemical techniques.
Since adriamycin is immunosuppressive and might alter the
acute phase response, we performed our initial studies in ne-
phrotic animals in the HN model. The antibody that creates HN
is directed to a receptor that is closely related to the a2M
receptor, the lipoprotein-like receptor protein (LRP) [41]. When
we found that a2M catabolism was increased in HN (to be
presented below), we extended our study to the ADR model to
assure that our results were not model dependent.
Determination of a2-macroglobulin and a1-inhibitor 3 levels in
hypooncotic states and after lipoprotein-like receptor protein
administration
The basal levels of a2M and a1-I3 were measured in 24 normal
control animals (C; Sprague-Dawley rats; N 5 24), 24 Nagase
analbuminemic rats (NAR) and 27 rats with passive Heymann
nephritis (HN). Passive Heymann nephritis was induced by intra-
peritoneal injection of sheep anti-FX IA antiserum as described
previously [4]. Proteins were measured by immunoelectrophoresis
as previously described [42].
Graded doses of endotoxin [lipopolysaccharide (LPS)] were
then administered as a bolus injection of 0.01, 0.15, 2.0, 25 or 250
mg/l00 g body wt into a tail vein. All injections were in 0.5 cc
volume. Saline was administered as the control. Animals were
fasted for 24 hours following injection since animals receiving the
two higher doses of LPS did not eat, and we wanted to assure that
differences in dietary intake played no role in the outcome. Blood
was obtained from a tail vein at 24 hours. Six animals in each
group were injected with each dose of LPS. The concentration of
a1-I3 was determined in the initial and final (24 hr) serum
samples in all groups of animals.
Determination of the effect of infusion of hyperoncotic human
albumin on the plasma levels of a2-macroglobulin and a1-
inhibitor 3
Maintaining plasma albumin concentration near the normal
range in nephrotic rats requires continuous infusion through a
catheter in the jugular vein tunneled subcutaneously [43]. In
preliminary studies during which saline was infused continuously
into NAR using subcutaneously tunneled catheters we found an
increase in the plasma concentration of acute phase proteins even
when meticulous care was paid to sterility of technique. No such
changes occurred when we administered either albumin or saline
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by intermittent bolus injections, since no surgery was required.
Thus, we chose to infuse albumin into NAR rather than add the
additional trauma of surgery to the model. We used NAR since no
urinary protein losses occur and, therefore, continuous infusion is
unnecessary to elevate plasma albumin concentration or p. Hy-
peroncotic human serum albumin (25%) (HSA) was injected
intravenously into 20 NAR to establish the effect on the plasma
concentration of a2M and a1-I3. Human serum albumin was
administered in three boluses into a tail vein using a #23 scalp
vein. The first bolus consisted of 400 mg/100 g body wt of human
albumin (to provide a normal total albumin mass) and the
following two of 200 mg/100 g body wt each. Boluses were
administered in 12-hour intervals. Albumin concentration was
maintained above 20 mg/ml. Serum was obtained for measure-
ment of a2M and a1-I3 initially and immediately prior to the third
dose of albumin in order to establish the effect of albumin
infusion on the plasma levels of these three proteins. Immediately
following administration of the third dose of albumin, LPS was
administered in graded doses to establish the effect of albumin
infusion on the response to LPS administration. Albumin was
infused in these animals 12 hours after LPS administration to
assure that albumin levels remained . 20 mg/ml throughout the
experimental period.
Quantitation of mRNA by dot blot hybridization
To obtain livers, rats were then anesthetized with sodium
pentobarbital (30 mg/kg) by intraperitoneal administration. The
abdomen was incised and the liver perfused retrograde with iced
saline. The liver was then removed, weighed and RNA was
extracted as described subsequently. Rat liver total RNA was then
isolated by homogenizing approximately 200 mg of tissue in
guanidinium isothiocyanate/Na acetate/mercaptoethanol using
the method of Srivastava, Srivastava and Schonfeld [44]. The
quality of the RNA isolated was assessed by visualization follow-
ing acridine orange staining on 1.5% agarose/formaldehyde gels,
as well as by Northern blotting using a probe for the constituitively
expressed GAPDH gene. Any samples showing significant degra-
dation were discarded. Probes for a1-I3, a2M, and GAPDH were
obtained from ATCC. Northern blots of 10 mg/lane of RNA were
initially run with each probe to determine hybridization condi-
tions and probe specificity; single bands of the expected molecular
weights were obtained prior to dot blotting. 32P-dCTP labeled
probes were made by random hexamer extension (RadPrime kit,
BRL). Ten microgram samples of each RNA were applied to a
dot blot manifold, fixed by NaOH, and hybridized overnight at
65°C with the appropriate probe. Blots were washed in 1 to 2%
sodium dodecyl sulfate/0.05 to 0.1 3 SSC at 65°C for one hour,
prior to developing for 2 to 16 hours on a Phospho-Imager plate.
Dot intensity was quantified by NIH Image analysis of the scanned
images. mRNA quantification is expressed as a ratio of the dot
intensity of specific genes under study to GAPDH, and expressed
ratios are the means of three to six measurements.
Rates of turnover of a2-macroglobulin and a1-I3 in nephrotic
and analbuminemic rats
a2-Macroglobulin was iodinated using chloramine T (Sigma) at
a molar ratio of 0.8 moles of 125 iodine (New England Nuclear)
to 1 mole of a2M. We then determined both kinetically and
electrophoretically that the iodinated macroglobulin was a mix-
ture of native and protease activated macroglobulin. Approxi-
mately 2 3 108 dpm of the iodinated protein was then injected
into a rat to remove the protease activated a2M, which has a
biological half life of approximately two to three minutes [45]. The
rat was anesthetized by intravenous administration of sodium
pentobarbital (20 mg/kg) immediately following injection of the
iodinated a2M. The abdomen was opened and the rat exsangui-
nated 15 minutes after administration of the iodinated protein.
Approximately 10 cc of blood was allowed to coagulate on ice, and
was then centrifuged and sterilized by millipore ultrafiltration and
used within three days. The serum was finally used as the labeled
protein.
Measurement of the a2M catabolic rate was performed by
intravenous injection into a tail vein (without anesthesia) of
between 106 and 2 3 106 dpm of serum derived as above. Blood
(50 ml) was obtained by nicking the tail at three minutes, 10
minutes, 30 minutes, 60 minutes, one hour, three hours, 10, 24, 48,
72 and up to 96 hours following injection or when residual counts
in plasma were # 5% of initial counts, whichever came first.
Metabolic clearance was determined as described previously for
other proteins [46], although the sum of exponentials was used
rather than the trapezoidal method for integration with a com-
mercially available curve fitting program (SAAM II; SAAM
institute, University of Washington, WA, USA). The product of
clearance, which was derived in volume per unit of time, and
plasma concentration of a given protein yielded the total quantity
of that protein removed per unit time. At steady state, the removal
rate (catabolism plus external loss) was the average rate of
synthesis over that time period [4].
Radioiodinated a1-I3 was prepared and biologically pre-
screened in the same way as was radioiodinated a2M. All radio-
label was isolated to a single protein migrating at 180 kDa, and
was assured both by Western blot using specific antiserum and
phosphoimaging of the labeled material. The iodinated a1-I3 was
then used for kinetic measurements. Urine was collected during
the kinetic measurement of a1-I3 clearance in nephrotic rats,
since we had previously established that substantial amounts of
this protein were lost in the urine (as much as 30% of total urinary
protein). Fractional catabolic rate (FCR) was the fraction of the
plasma pool catabolized per unit of time. Urinary losses of a1-I3
were measured in nephrotic rats when the turnover of this protein
was studied, and these losses were subtracted from total turnover
in order to establish the fractional catabolic rate of a1-I3 in
nephrotic animals.
Statistical methods
Data were first analyzed for normality of distribution using the
Kolmogorov-Smirnov test for normality (using Sigma Stat, a
commercial statistics program; Jandel Corp., San Rafael CA,
USA). If data were non-normally distributed they were analyzed
by the Kruskal-Wallis one way analysis of variance on ranks. If
differences were detected multiple groups were then analyzed
using Dunn’s method for multiple comparisons. The Mann-
Whitney sum test was used to make comparisons when only two
groups were analyzed. Differences were considered statistically
significant at P , 0.05. Regression analysis was performed using
the methods of least squares. Results of normally distributed data
are presented as mean 6 SEM.
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RESULTS
Macroglobulin levels, synthesis, and catabolism in
hypoalbuminemic states
Basal levels of a2M were significantly greater in HN (2284 6
217 mg/ml) than in NAR (291 6 13, P , 0.001) and were lowest
in C (84 6 4.4, P , 0.001 compared to both HN and NAR) prior
to administration of either LPS or albumin. Basal a1-I3 was also
increased significantly in both NAR (22.7 6 0.4 mg/ml) and HN
(21.2 6 0.7 mg/ml) compared to C (10.7 6 0.5 mg/ml). The
concentration of a1-I3 in HN was about half of that of albumin in
normal animals and made up the bulk of plasma protein mass.
The increase in a1-I3 was surprising considering that it is normally
either constituitively expressed or down-regulated by inflamma-
tion [26–29].
Effect of lipopolysaccharide administration
One mechanism that could be responsible for increased a2M
levels and that of other acute phase proteins could be an
alteration in the sensitivity of hypoalbuminemic organisms to LPS.
This lipophilic substance could potentially be bound to albumin
and thus hypoalbuminemia could potentially augment the avail-
ability of this compound to its target cells. If this were correct, the
amount of LPS necessary to cause a half maximal response should
increase following replacement of albumin to the animal. For this
reason we tested a dose response relationship between changed
levels of a2M following the administration of graded doses LPS as
well as the effect of albumin infusion on this response in NAR. It
was also not an effect of plasma pool dilution, since the concen-
tration of another unrelated acute phase protein, a1 acid glyco-
protein, did not change (data not shown).
Lipopolysaccharide caused a dose related increase in plasma
a2M in C, NAR, and HN animals with a half maximal response
between 0.15 and 2 mg LPS/l00 g body wt, independent of any
group (Fig. 1). Thus, the sensitivity to LPS was the same in all
groups. The absolute final level of a2M and net change in plasma
a2M level was in large part a consequence of the initial level. The
absolute final level of a2M was greatest in HN, while the percent
increase (19-fold) was greatest in C and intermediate in NAR
(11-fold), and least in HN (2.6-fold). Infusion of LPS into NAR
previously treated with albumin led to the same final a2M
concentration as in C.
Effect of albumin infusion
Albumin infusion significantly reduced both a1-I3 and a2M
levels in NAR (Fig. 2). The decrease in a1-I3 concentration was
the same as that produced by LPS administration but was not a
result of a generalized acute phase response, since a2M levels also
decreased significantly following albumin infusion (Fig. 2), but
rose markedly after LPS treatment (Fig. 1). Hence, correction of
hypoalbuminemia attenuated the elevations of both macroglobu-
lins in NAR.
Gene expression
Surprisingly, although the concentration of a2M was increased
by 27-fold in HN compared to C, the increase in the concentration
of a2M mRNA in liver was quite small (approximately 2-fold; Fig.
3). Administration of LPS produced a robust increase in a2M
RNA in liver, demonstrating that the expected response to a
stimulus known to increase transcription of this protein [22, 23,
26] was maintained. Increased levels of a2M in hypoalbuminemic
states must then be a consequence of either increased efficiency of
translation of the protein from previously extant hepatic message
or altered hepatic protein processing/secretion or a decrease in
the fractional catabolic rate (FCR) of the protein.
Rats with HN had an approximate 50% increase in a1-I3
mRNA (Fig. 4), inadequate to entirely explain the doubling in
serum concentration. The mRNA levels in NAR rats did not
differ significantly from control, yet serum concentration was also
increased by approximately twofold. In all groups, a1-I3 mRNA
levels decreased following LPS administration, as would be ex-
pected in this negative acute phase reactant (Fig. 4). The doubled
serum concentration of a1-I3 in NAR and nephrotic animals is at
least in part a consequence of post-transcriptional events, as in
a2M. Post-transcriptional events that might alter the concentra-
tion of a protein in plasma include changes in the protein
fractional catabolic rate.
Turnover of a2-macroglobulin and a1-inhibitor 3 in NAR and
nephrotic rats
To determine whether changes in synthesis or in FCR were
responsible for increasing levels of a2M and a1-I3, we measured
the turnover of the iodinated proteins at steady state. These
measurements will yield both a FCR and a synthesis rate at steady
state [4, 6, 46]. Initially we determined that a2M FCR was
increased significantly in HN, an unanticipated finding (Table 1).
Since HN is initiated by an antibody to GP330, a protein with
Fig. 1. Increase in plasma a2-macroglobulin level 24 hours after admin-
istration of graded doses of lipopolysaccharide (LPS) into a tail vein. Six
rats (all male) were injected with each dose of LPS (0.01 mg/100 g body
weight, 2 mg/100 g body weight, 25 mg/100 g body weight and 250 mg/100
g body weight) or saline. All animals were fasted for the following 24 hours
but allowed free access to water. Abbreviations are: HN (V), Heymann’s
nephritis; NAR (M), rats with hereditary analbuminemia; control (c),
normal Sprague-Dawley rats; NAR 1 Alb (M• ), NAR rats that received i.v.
albumin infused for 24 hours prior to and following the administration of
LPS to maintain a serum albumin concentration . 20 mg/ml. *P , 0.05 vs.
control; †P , 0.05 vs. NAR. Data are mean 6 SEM.
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close homology to the a2M receptor [41], we were concerned that
the HN model might produce artifactual results when measuring
macroglobulin catabolism. For this reason we performed the rest
of our catabolic studies using the adriamycin model.
a2-Macroglobulin was increased approximately 20-fold in NAR
and 40-fold in HN and 50-fold in ADR (Table 1). The elevated
level of a2M was entirely a consequence of increased synthesis
(Table 1). The synthetic rate was directly and linearly propor-
tional to plasma concentration (Fig. 5). In contrast, a2M FCR was
independent of plasma concentration and not different in con-
trols, NAR, or ADR, but was significantly increased in HN (Table
1), a change that should have favored a decreased plasma
concentration of this protein in this group of animals. Thus, a
reduction in FCR played no role in supporting an increased
plasma concentration of this protein. a2-Macroglobulin is suffi-
ciently large (720 kDa) so that it is not lost in the urine in
significant amounts even in nephrotic animals (data not shown).
The mechanism for the unexpected elevations in a1-I3 plasma
concentrations was more complex. The plasma concentration of
a1-I3 was significantly greater in ADR than in NAR despite
significant urinary losses in nephrosis (Table 2). Urinary losses of
a1-I3 were about 20% that of albumin, representing a large
fraction of non-albumin protein in the urine of nephrotic rats. The
Fig. 2. Effect of infusion of albumin or
lipopolysaccharide on plasma a1-inhibitor 3
(a1-I3) concentration and of albumin on
plasma a2-macroglobulin (a2M) concentration
in rats with hereditary albuminemia (NAR).
Blood was drawn from a tail vein prior to
infusion and then at 24 hours. Hyperoncotic
(25%) human serum albumin was infused first
as a bolus of 400 mg/100 g body wt and then a
second dose of 200 mg/100 g body wt was
administered 12 hours later. No albumin was
administered to the rats receiving LPS 250 mg/
100 g body wt.
Fig. 3. Hepatocyte mRNA levels of a2-macroglobulin (a2M) in control
and hypooncotic states. Total RNA from the experimental groups was dot
blotted and analyzed with radioactive probes for a2M and for the
constituitive control gene GAPDH. Data are expressed as mean a2M/
GAPDH ratio (means 6 SEM from at least 3 experiments). (f saline-
injected; o LPS-injected; *P , 0.05 vs. no LPS.)
Fig. 4. Hepatocyte mRNA levels of a1-inhibitor 3 (a1-I3) in control and
hypooncotic states. Total RNA from the experimental groups was dot
blotted and analyzed with radioactive probes for a1-I3 and for the
constituitive control gene GAPDH. Data are expressed as a mean
a1-I3/GAPDH ratio (means 6 SEM from at least 3 experiments). (f
saline-injected; o LPS-injected; *P , 0.05 vs. no LPS; 1P , 0.05 vs.
control.)
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rate of synthesis of a1-I3 was increased twofold in both NAR and
ADR and was proportional to serum concentration (Fig. 6). In
contrast, FCR of a1-I3 was significantly decreased in ADR, in
sharp contrast to what occurs for other proteins lost into the urine
(transferrin and albumin), where the fractional catabolic rate
sharply increases [4, 8, 47, 48]. a1-Inhibitor 3 FCR tended to also
decrease in NAR, but this did not achieve statistical significance
(Table 2). For all groups there was an inverse relationship
between a1-I3 concentration and its FCR (2r 5 0.66, P , 0.01).
In contrast to a2M the mechanism of increased plasma concen-
tration of a1-I3 was multifactorial, with both increased synthesis
and decreased FCR contributing to its increased plasma levels.
DISCUSSION
In both the nephrotic syndrome and in hereditary analbumin-
emia the concentrations of many liver derived proteins are
increased in plasma [14]. In the situation of NAR, where no
urinary protein losses occurs, plasma protein concentration is
essentially the same as in non-nephrotic animals [49], and the
relationship between plasma protein concentration and p is also
nearly normal [14], suggesting that a regulatory mechanism(s)
may defend plasma protein concentration or p when the albumin
concentration is reduced either as a consequence of lack of
synthesis or external losses. The increased synthesis of proteins
that replace albumin takes place primarily or exclusively in the
liver. Furthermore, transcription of a group of liver derived
proteins (albumin [5, 18, 19], transferrin [9], apo A-I [16], and
fibrinogen [17]) is increased, suggesting that transcriptional up-
regulation of a group of proteins might be regulated in a manner
analogous to what occurs in the case of the acute phase response.
Marsh and Sparks suggested that the hyperlipidemia of the
nephrotic syndrome was, at least in part, a consequence of a
generalized hepatic response [50]. However, they found that not
all liver derived proteins behaved in the same way. The increase in
synthesis of apo B and apo E was not as great as was the increase
in apo A-I synthesis, while apo C synthesis was not increased at all
[51].
While small amounts of a2M are synthesized in extrahepatic
tissue [24, 52], it is unlikely that these tissues contribute impor-
tantly to increased plasma concentrations of this protein. a1-
Inhibitor 3 is only liver derived [53]. An increase in plasma
concentration of either protein then must reflect either an in-
crease in hepatic protein synthesis or a decrease in the FCR for
the specific protein or both (as occurs for apo A-I) [6]. Since
Vaziri noted that a2M concentration was increased in nephrotic
patients, we speculated that increased a2M would be a conse-
quence of increased synthesis and that this regulation would
transcriptional, as in the case of another class II acute phase
protein fibrinogen [17]. Furthermore, since transcription of albu-
min, apo A-I, and transferrin were increased, we speculated that
that of a1-I3 would also be regulated similarly. a1-Inhibitor 3 is
smaller than a2M and is thus capable of contributing more to p.
It is also present in relatively high concentrations in rodents [28,
29] and hence could play a significant role in maintaining plasma
protein content. We have now established that synthesis of both of
these protease inhibitors is indeed increased in hypoalbuminemic
states, and in the case of a2M synthesis rates are increased
massively. Plasma a2M concentration in nephrotic rats not ex-
posed to LPS is greater than in normal animals given a dose of
LPS that induces a maximal increase in plasma a2M levels. Thus,
hypoalbuminemia is a more effective means of increasing plasma
a2M than is the acute phase response, normally considered to be
the primary stimulus for synthesis of this protein. The response to
hypoalbuminemia is not a consequence of increased sensitivity of
animals with low albumin levels to LPS since the dose response
curve is not shifted. Furthermore, the mechanisms for increased
synthesis resulting from hypoalbuminemia and from the acute
phase response are different. While LPS administration induces a
robust increase in a2M mRNA in the livers of both nephrotic and
normal rats, hepatic a2M mRNA levels are increased only slightly
Table 1. a2-Macroglobulin metabolism in normal analbuminemic and
nephrotic rats
Group
Serum
concentration
of a2
macroglobulin
mg/ml
Synthesis
mg/100 g body
wt/hr
FCR
% plasma
pool/hr
Control 0.0868 6 0.0275 0.0443 6 0.0175 9.16 6 1.125
N 5 8
NAR 1.56 6 0.226a 0.531 6 0.111a 9.29 6 1.127
N 5 8
Adriamycin 3.88 6 0.31ab 2.261 6 0.341ab 10.93 6 1.63
N 5 6
Heymann
nephritis
2.07 6 0.90a 1.58 6 0.703ab 19.34 6 1.344abc
N 5 3
Data are means 6 SEM.
a P , 0.05 vs. Control
b P , 0.05 vs. NAR
c P , 0.05 vs. Adriamycin
Fig. 5. Relationship between plasma a2-macroglobulin (a2M) concen-
tration and its rate of synthesis measured as the product of clearance of
125[I]labeled native a2M and its plasma concentration. Symbols are: (F)
control; (M) NAR; () HN; (²) ADR. The solid line denotes the least
squares regression, and dotted lines are the 95% confidence limit. (r 5
0.903; P , 0.001)
Stevenson et al: Macroglobulin synthesis in hypoalbuminemia72
in the nephrotic syndrome or NAR, yet a2M synthesis is increased
by '50-fold.
The biology of a1-I3 was unexpected. The rate of synthesis of
a1-I3 was quite high, similar to that reported for albumin in
normal animals [4, 5]. a1-Inhibitor 3 is small enough for substan-
tial amounts to be lost in the urine of nephrotic rats, and we find
its urinary loss to be about 20% that of albumin. Despite these
urinary losses, plasma concentration increased to levels compara-
ble to that of albumin in non-nephrotic animals. This increase in
a1-I3 plasma level was a consequence both of increased synthesis
and decreased FCR. This protein is a negative acute phase
protein, and as far as we are aware there is no known stimulus to
increase either its levels or its rate of synthesis save the conditions
described here: the nephrotic syndrome and analbuminemia. The
observation that plasma a1-I3 levels decrease following adminis-
tration of albumin and that synthesis is increased both in analbu-
minemic and nephrotic rats suggests that the rate of synthesis of
this protein is in part regulated by either albumin concentration or
p. Like a2M, this regulation is at least in part post-transcriptional,
suggesting that reduced albumin concentration or p either di-
rectly or indirectly alters hepatic protein processing or the effi-
ciency of translation of some proteins from existent mRNA in
liver.
The nephrotic syndrome results in changes not only in synthesis
of plasma proteins, but also in their FCRs. Fractional catabolic
rate for a protein is a function of the catabolic rate constant. An
FCR that remains constant despite changes in the plasma con-
centration of a given protein is a consequence of unchanging first
order kinetics that are neither saturated nor regulated. Albumin is
a protein whose plasma concentration is in part regulated or
supported by alterations in its FCR. When albumin is reduced as
a consequence of reduced synthesis, FCR decreases serving to
mitigate the decrease in albumin concentration that would other-
wise result from a decrease in synthesis [54]. In contrast, when
albumin levels are increased as a result of albumin infusion FCR
increases and returns albumin levels back toward normal. In the
nephrotic syndrome this positive relationship between albumin
concentration and its FCR is inverted [48, 55, 56], leading to a
paradoxical increasing FCR when serum albumin is reduced. This
is also true for transferrin, another protein lost extensively in the
urine in the nephrotic syndrome [8, 9]. This altered relationship
between the serum concentration of these intermediate sized
proteins and their FCRs in the nephrotic syndrome has been
postulated to result from their increased renal catabolism. It was
postulated that a much larger quantity of these proteins was
filtered than could be found in urine, but that a large quantity was
reabsorbed by renal tubular cells and catabolized there [47, 57,
58]. That hypothesis has not been proven, and indeed there are
data suggesting that nearly all of the filtered albumin finds its way
into urine [59–63]. Nevertheless, the FCRs of proteins that are
lost extensively in the urine in the nephrotic syndrome are
generally increased [4, 8, 55, 58, 59, 64], with the exception now of
a1-I3. It is not known whether the decreased a1-I3 FCR is a
regulated process or whether the catabolic site that normally
processes this protein is saturated or nearly so at physiological
a1-I3 concentrations. Nevertheless, a reduced FCR for this
protein lost in urine is both novel and contributes to increasing its
concentration in plasma. In contrast to a1-I3, a2M FCR is
independent of plasma concentration with the exception of HN.
We believe that the increased FCR in HN may be model
dependent due to the interaction between macroglobulins and the
LRP, but clearly an increase in FCR would favor a reduced, not
an increased a2M concentration.
The effect of alterations in albumin concentration or p on
Table 2. a1-Inhibitor 3 (a1-I3) metabolism in normal analbuminemic and adriamycin-induced nephrotic rats
Group
Serum a1-I3 Urinary a1-I3 Urinary albumin
a1-I3 Synthesis
mg/100 g body wt/hr
FCR % plasma
pool/hrmg/ml
Control 16.4 6 0.30 ND ND 5.41 6 0.82 8.30 6 0.85
N 5 5
NAR 29.2 6 1.7a ND ND 9.27 6 1.0a 6.13 6 0.47
N 5 5
Adriamycin 36.4 6 3.1a 48.5 6 10.2 279 6 47 10.26 6 1.1a 5.84 6 0.63a
N 5 5
Means 6 SEM. ND is not done.
a Difference from Control (P , 0.05)
Fig. 6. Relationship between plasma a1-inhibitor 3 (a1-I3) concentra-
tion and its rate of synthesis measured as the product of clearance of
125[I]labeled native a1-I3 and its plasma concentration. Symbols are: (F)
control; (M) NAR; () HN; (²) ADR. The solid line denotes the least
squares regression, and dotted lines are the 95% confidence limit. (r 5
0.817; P , 0.001)
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hepatocyte protein synthesis and secretion is complex, and that
increased synthesis of these hepatic proteins serves a role to
support plasma protein concentration at or near the normal range
despite either the absence of effective albumin synthesis or the
urinary losses of the proteins that normally make up the bulk of
plasma protein mass. Were it not for these complex responses by
the liver both hereditary analbuminia and the nephrotic syndrome
would have a much greater impact on total plasma protein levels.
The binding function of these macroglobulins for cytokines,
growth factors, proteases, and metals may also play a role in the
pathophysiology of these syndromes.
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